Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

Emerging Therapies Targeting Pain and Obesity Take Flight

July 02, 2025

Following Vertex Pharmaceuticals’ landmark approval of a selective sodium channel blocker addressing acute pain, SiteOne Therapeutics has garnered significant investment and agreed to a potential...

Novel Cancer Immunotherapies and Biomarkers Surface in Clinical Research

July 02, 2025

Recent studies uncover various innovations improving cancer therapy and diagnosis. Biokin achieved a Phase 3 success with a bispecific antibody-drug conjugate licensed to Bristol Myers Squibb. New...

AI and Automation Innovate Neuroscience and Neurodegenerative Disease Research

July 02, 2025

Cutting-edge interdisciplinary efforts are leveraging AI to elucidate and treat neurological disorders. Digital speech biomarker studies quantify levodopa response variability in Parkinson’s...

AbbVie’s $2.1 Billion Bet on In Vivo CAR-T Therapy

July 02, 2025

AbbVie announced the acquisition of Capstan Therapeutics for up to $2.1 billion, aiming to deepen its exploration of in vivo CAR-T therapies—a promising approach that engineers immune cells...

AI Advances in Cancer Detection and Diagnostics

July 02, 2025

Recent breakthroughs illustrate AI’s expanding role in oncology, with institutions developing models for early cancer detection and enhanced diagnostic accuracy. The University of Sharjah unveiled...

Psychedelic Therapies Gain Mid-Stage Clinical Momentum

July 02, 2025

Beckley Psytech and Atai Life Sciences reported positive Phase 2b results for the psychedelic compound BPL-003 (intranasal mebufotenin) in treatment-resistant depression, exceeding efficacy...

Genetic Damage from Chemotherapy Illuminates Safer Treatment Paths

July 02, 2025

Groundbreaking studies from the Wellcome Sanger Institute and collaborators have characterized distinct mutational signatures induced by diverse chemotherapy drugs on healthy blood cells,...

New Agents and Strategies in Obesity and Metabolic Disease

July 02, 2025

Innovative approaches to obesity treatment are emerging, including Syntis Bio’s novel intestinal coating technology mimicking gastric bypass effects, funded with $38 million to advance clinical...

Regulatory Shifts and Industry Financing Highlights

July 02, 2025

Significant industry movements include Sage Therapeutics planning layoffs of most staff following acquisition by Supernus Pharmaceuticals, underscoring volatility in neuropharma. Imagene AI raised...

Innovations in Gene Editing and RNA Therapeutics

July 02, 2025

Technological advances are accelerating gene and RNA-based therapies. Researchers demonstrated a near-infrared light activatable CRISPR system enabling precise spatiotemporal genome editing....

Single-Atom and Molecular Advances in Cancer Therapy

July 02, 2025

Cutting-edge cancer research highlights include the use of single-atom engineering to create radiotherapy-activated immune prodrugs that boost targeted immune responses. Studies revealed...

Climate Change and Environmental Impact on Health and Agriculture

July 02, 2025

New studies shed light on environmental challenges affecting health and food systems. Research revealed gut bacteria bioaccumulate harmful PFAS pollutants, presenting novel microbiome-targeted...

AbbVie Buys In Vivo CAR-T Developer Capstan for $2.1 Billion

July 02, 2025

AbbVie has announced a $2.1 billion acquisition of Capstan Therapeutics, a startup advancing in vivo CAR-T therapies aimed at autoimmune diseases and cancer. Capstan’s lead candidate CPTX2309, an...

Phase 2b Trial Shows Psychedelic Mebufotenin Cuts Depression Symptoms

July 02, 2025

Beckley Psytech and Atai Life Sciences reported positive Phase 2b trial results for BPL-003, an intranasal formulation of the psychedelic mebufotenin, significantly reducing symptoms in...

New Chemotherapy Mutational Signatures Reveal Long-Term Risks

July 02, 2025

A landmark study led by the Wellcome Sanger Institute and University of Cambridge has systematically characterized DNA damage patterns caused by various chemotherapy drugs in healthy blood cells....

Moderna’s mRNA Flu Vaccine Shows Superior Efficacy in Phase 3 Trial

July 02, 2025

Moderna announced that its mRNA-based seasonal influenza vaccine, mRNA-1010, demonstrated a 27% reduction in influenza-like illness compared to a standard marketed vaccine in individuals aged 50...

Machine Learning Models Enhance Cancer Detection and Prognosis

July 02, 2025

Recent advances in artificial intelligence have produced models capable of improving diagnosis and outcome prediction in oncology. This includes an AI platform for early pancreatic cancer...

Parkinson’s Disease Research Yields Molecular and Therapeutic Insights

July 02, 2025

Multiple studies reveal new understanding of Parkinson’s disease (PD) mechanisms and interventions. These include digital speech biomarkers measuring levodopa effects, enzyme inhibition restoring...

Advances in Sustainable and Biomedical Materials Science

July 02, 2025

Innovative research is increasing the ease and scope of creating sustainable biomaterials and medical textiles. Developments include cellulose-derived biodegradable foams, breathable protective...

Genetic and Molecular Targets Propel Cancer and Immunotherapy Research

July 02, 2025

Cutting-edge studies identify novel molecular mechanisms and therapeutic targets across cancer and immunology fields. Topics include DLK1 as an immunotherapy target in adrenocortical carcinoma,...